nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—ankylosing spondylitis	0.67	1	CbGaD
Naloxone—SLCO1A2—Prednisolone—ankylosing spondylitis	0.0471	0.154	CbGbCtD
Naloxone—SLCO1A2—Prednisone—ankylosing spondylitis	0.0445	0.145	CbGbCtD
Naloxone—SLCO1A2—Dexamethasone—ankylosing spondylitis	0.0278	0.0907	CbGbCtD
Naloxone—ALB—Prednisone—ankylosing spondylitis	0.023	0.075	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—ankylosing spondylitis	0.0223	0.0729	CbGbCtD
Naloxone—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0199	0.0648	CbGbCtD
Naloxone—ABCB1—Betamethasone—ankylosing spondylitis	0.0129	0.0421	CbGbCtD
Naloxone—ABCB1—Prednisolone—ankylosing spondylitis	0.0127	0.0416	CbGbCtD
Naloxone—ABCB1—Prednisone—ankylosing spondylitis	0.012	0.0393	CbGbCtD
Naloxone—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0119	0.0388	CbGbCtD
Naloxone—ALB—Methotrexate—ankylosing spondylitis	0.0115	0.0376	CbGbCtD
Naloxone—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0111	0.0362	CbGbCtD
Naloxone—CYP3A4—Triamcinolone—ankylosing spondylitis	0.00902	0.0294	CbGbCtD
Naloxone—CYP3A4—Betamethasone—ankylosing spondylitis	0.00774	0.0252	CbGbCtD
Naloxone—CYP3A4—Prednisolone—ankylosing spondylitis	0.00763	0.0249	CbGbCtD
Naloxone—ABCB1—Dexamethasone—ankylosing spondylitis	0.00751	0.0245	CbGbCtD
Naloxone—CYP3A4—Prednisone—ankylosing spondylitis	0.00721	0.0235	CbGbCtD
Naloxone—ABCB1—Methotrexate—ankylosing spondylitis	0.00604	0.0197	CbGbCtD
Naloxone—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0045	0.0147	CbGbCtD
Naloxone—Drug dependence—Methylprednisolone—ankylosing spondylitis	0.000985	0.0557	CcSEcCtD
Naloxone—Drug dependence—Betamethasone—ankylosing spondylitis	0.000896	0.0506	CcSEcCtD
Naloxone—Drug dependence—Dexamethasone—ankylosing spondylitis	0.000896	0.0506	CcSEcCtD
Naloxone—Drug dependence—Prednisone—ankylosing spondylitis	0.00078	0.0441	CcSEcCtD
Naloxone—Withdrawal syndrome—Prednisone—ankylosing spondylitis	0.000519	0.0293	CcSEcCtD
Naloxone—Sneezing—Triamcinolone—ankylosing spondylitis	0.000495	0.028	CcSEcCtD
Naloxone—Encephalopathy—Methotrexate—ankylosing spondylitis	0.000282	0.0159	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisolone—ankylosing spondylitis	0.000265	0.015	CcSEcCtD
Naloxone—TLR4—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000258	0.0441	CbGpPWpGaD
Naloxone—Pulmonary oedema—Triamcinolone—ankylosing spondylitis	0.000244	0.0138	CcSEcCtD
Naloxone—Pulmonary oedema—Methylprednisolone—ankylosing spondylitis	0.000243	0.0138	CcSEcCtD
Naloxone—Pulmonary oedema—Dexamethasone—ankylosing spondylitis	0.000221	0.0125	CcSEcCtD
Naloxone—Pulmonary oedema—Betamethasone—ankylosing spondylitis	0.000221	0.0125	CcSEcCtD
Naloxone—Cardiac arrest—Prednisolone—ankylosing spondylitis	0.000206	0.0116	CcSEcCtD
Naloxone—TLR4—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000201	0.0344	CbGpPWpGaD
Naloxone—Pulmonary oedema—Prednisone—ankylosing spondylitis	0.000193	0.0109	CcSEcCtD
Naloxone—Irritability—Methylprednisolone—ankylosing spondylitis	0.000189	0.0107	CcSEcCtD
Naloxone—Cardiac arrest—Triamcinolone—ankylosing spondylitis	0.000189	0.0107	CcSEcCtD
Naloxone—Hyperkinesia—Prednisone—ankylosing spondylitis	0.000189	0.0107	CcSEcCtD
Naloxone—Cardiac arrest—Methylprednisolone—ankylosing spondylitis	0.000189	0.0107	CcSEcCtD
Naloxone—Irritability—Betamethasone—ankylosing spondylitis	0.000172	0.00973	CcSEcCtD
Naloxone—Irritability—Dexamethasone—ankylosing spondylitis	0.000172	0.00973	CcSEcCtD
Naloxone—Cardiac arrest—Betamethasone—ankylosing spondylitis	0.000172	0.0097	CcSEcCtD
Naloxone—Cardiac arrest—Dexamethasone—ankylosing spondylitis	0.000172	0.0097	CcSEcCtD
Naloxone—TLR4—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000169	0.0289	CbGpPWpGaD
Naloxone—Coma—Methotrexate—ankylosing spondylitis	0.000165	0.00934	CcSEcCtD
Naloxone—Pulmonary oedema—Methotrexate—ankylosing spondylitis	0.000161	0.0091	CcSEcCtD
Naloxone—CREB1—Regulation of nuclear SMAD2/3 signaling—RUNX3—ankylosing spondylitis	0.00016	0.0274	CbGpPWpGaD
Naloxone—Irritability—Prednisone—ankylosing spondylitis	0.00015	0.00848	CcSEcCtD
Naloxone—Cardiac arrest—Prednisone—ankylosing spondylitis	0.000149	0.00845	CcSEcCtD
Naloxone—Sweating—Methylprednisolone—ankylosing spondylitis	0.000147	0.00829	CcSEcCtD
Naloxone—Hallucination—Methylprednisolone—ankylosing spondylitis	0.000137	0.00772	CcSEcCtD
Naloxone—TLR4—Immune System—KIR3DL1—ankylosing spondylitis	0.000134	0.0229	CbGpPWpGaD
Naloxone—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000127	0.0072	CcSEcCtD
Naloxone—Irritability—Methotrexate—ankylosing spondylitis	0.000125	0.00709	CcSEcCtD
Naloxone—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000125	0.00704	CcSEcCtD
Naloxone—Hallucination—Betamethasone—ankylosing spondylitis	0.000124	0.00702	CcSEcCtD
Naloxone—Hallucination—Dexamethasone—ankylosing spondylitis	0.000124	0.00702	CcSEcCtD
Naloxone—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000124	0.00699	CcSEcCtD
Naloxone—Depression—Prednisone—ankylosing spondylitis	0.000121	0.00683	CcSEcCtD
Naloxone—TLR4—Innate Immune System—CARD9—ankylosing spondylitis	0.000121	0.0207	CbGpPWpGaD
Naloxone—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.00012	0.0068	CcSEcCtD
Naloxone—CREB1—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.000118	0.0201	CbGpPWpGaD
Naloxone—Angiopathy—Betamethasone—ankylosing spondylitis	0.000113	0.0064	CcSEcCtD
Naloxone—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000113	0.0064	CcSEcCtD
Naloxone—Convulsion—Prednisolone—ankylosing spondylitis	0.000113	0.00638	CcSEcCtD
Naloxone—Hypertension—Prednisolone—ankylosing spondylitis	0.000112	0.00636	CcSEcCtD
Naloxone—Hallucination—Prednisone—ankylosing spondylitis	0.000108	0.00611	CcSEcCtD
Naloxone—CREB1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000107	0.0183	CbGpPWpGaD
Naloxone—ESR1—Regulation of nuclear SMAD2/3 signaling—RUNX3—ankylosing spondylitis	0.000105	0.018	CbGpPWpGaD
Naloxone—Convulsion—Triamcinolone—ankylosing spondylitis	0.000104	0.00587	CcSEcCtD
Naloxone—Tachycardia—Prednisolone—ankylosing spondylitis	0.000104	0.00586	CcSEcCtD
Naloxone—Convulsion—Methylprednisolone—ankylosing spondylitis	0.000104	0.00585	CcSEcCtD
Naloxone—Hypertension—Triamcinolone—ankylosing spondylitis	0.000103	0.00584	CcSEcCtD
Naloxone—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000103	0.00583	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000103	0.00581	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000101	0.00571	CcSEcCtD
Naloxone—Depression—Methotrexate—ankylosing spondylitis	0.000101	0.0057	CcSEcCtD
Naloxone—Flushing—Prednisone—ankylosing spondylitis	0.000101	0.0057	CcSEcCtD
Naloxone—CREB1—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.0001	0.0172	CbGpPWpGaD
Naloxone—Angiopathy—Prednisone—ankylosing spondylitis	9.87e-05	0.00558	CcSEcCtD
Naloxone—Sweating—Methotrexate—ankylosing spondylitis	9.71e-05	0.00548	CcSEcCtD
Naloxone—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	9.57e-05	0.00541	CcSEcCtD
Naloxone—Paraesthesia—Prednisolone—ankylosing spondylitis	9.55e-05	0.00539	CcSEcCtD
Naloxone—Tachycardia—Triamcinolone—ankylosing spondylitis	9.54e-05	0.00539	CcSEcCtD
Naloxone—Mental disorder—Prednisone—ankylosing spondylitis	9.53e-05	0.00538	CcSEcCtD
Naloxone—Tachycardia—Methylprednisolone—ankylosing spondylitis	9.52e-05	0.00538	CcSEcCtD
Naloxone—CREB1—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	9.48e-05	0.0162	CbGpPWpGaD
Naloxone—Skin disorder—Methylprednisolone—ankylosing spondylitis	9.48e-05	0.00535	CcSEcCtD
Naloxone—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	9.45e-05	0.00534	CcSEcCtD
Naloxone—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	9.43e-05	0.00533	CcSEcCtD
Naloxone—Convulsion—Dexamethasone—ankylosing spondylitis	9.42e-05	0.00532	CcSEcCtD
Naloxone—Convulsion—Betamethasone—ankylosing spondylitis	9.42e-05	0.00532	CcSEcCtD
Naloxone—Hypertension—Dexamethasone—ankylosing spondylitis	9.39e-05	0.0053	CcSEcCtD
Naloxone—Hypertension—Betamethasone—ankylosing spondylitis	9.39e-05	0.0053	CcSEcCtD
Naloxone—Pain—Prednisolone—ankylosing spondylitis	9.09e-05	0.00514	CcSEcCtD
Naloxone—CREB1—AP-1 transcription factor network—IL10—ankylosing spondylitis	8.89e-05	0.0152	CbGpPWpGaD
Naloxone—Paraesthesia—Triamcinolone—ankylosing spondylitis	8.78e-05	0.00496	CcSEcCtD
Naloxone—Paraesthesia—Methylprednisolone—ankylosing spondylitis	8.76e-05	0.00495	CcSEcCtD
Naloxone—Dyspnoea—Triamcinolone—ankylosing spondylitis	8.72e-05	0.00493	CcSEcCtD
Naloxone—Nervous system disorder—Dexamethasone—ankylosing spondylitis	8.7e-05	0.00492	CcSEcCtD
Naloxone—Nervous system disorder—Betamethasone—ankylosing spondylitis	8.7e-05	0.00492	CcSEcCtD
Naloxone—Agitation—Prednisone—ankylosing spondylitis	8.7e-05	0.00492	CcSEcCtD
Naloxone—Tachycardia—Betamethasone—ankylosing spondylitis	8.66e-05	0.00489	CcSEcCtD
Naloxone—Tachycardia—Dexamethasone—ankylosing spondylitis	8.66e-05	0.00489	CcSEcCtD
Naloxone—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	8.58e-05	0.00485	CcSEcCtD
Naloxone—Hyperhidrosis—Betamethasone—ankylosing spondylitis	8.58e-05	0.00485	CcSEcCtD
Naloxone—CREB1—Transcription factor regulation in adipogenesis—TNF—ankylosing spondylitis	8.54e-05	0.0146	CbGpPWpGaD
Naloxone—Cardiac disorder—Methotrexate—ankylosing spondylitis	8.44e-05	0.00477	CcSEcCtD
Naloxone—CREB1—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	8.4e-05	0.0144	CbGpPWpGaD
Naloxone—Pain—Triamcinolone—ankylosing spondylitis	8.36e-05	0.00472	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—ankylosing spondylitis	8.25e-05	0.00466	CcSEcCtD
Naloxone—Convulsion—Prednisone—ankylosing spondylitis	8.2e-05	0.00463	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—ankylosing spondylitis	8.19e-05	0.00463	CcSEcCtD
Naloxone—Hypertension—Prednisone—ankylosing spondylitis	8.17e-05	0.00462	CcSEcCtD
Naloxone—Chills—Methotrexate—ankylosing spondylitis	8.16e-05	0.00461	CcSEcCtD
Naloxone—TLR4—Immune System—IL1R2—ankylosing spondylitis	8.1e-05	0.0139	CbGpPWpGaD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	8e-05	0.00452	CcSEcCtD
Naloxone—Paraesthesia—Betamethasone—ankylosing spondylitis	7.97e-05	0.0045	CcSEcCtD
Naloxone—Paraesthesia—Dexamethasone—ankylosing spondylitis	7.97e-05	0.0045	CcSEcCtD
Naloxone—Mental disorder—Methotrexate—ankylosing spondylitis	7.96e-05	0.0045	CcSEcCtD
Naloxone—CREB1—Regulation of nuclear SMAD2/3 signaling—IL10—ankylosing spondylitis	7.91e-05	0.0135	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	7.9e-05	0.0135	CbGpPWpGaD
Naloxone—CREB1—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	7.83e-05	0.0134	CbGpPWpGaD
Naloxone—Body temperature increased—Triamcinolone—ankylosing spondylitis	7.73e-05	0.00437	CcSEcCtD
Naloxone—Abdominal pain—Methylprednisolone—ankylosing spondylitis	7.71e-05	0.00436	CcSEcCtD
Naloxone—CREB1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	7.7e-05	0.0132	CbGpPWpGaD
Naloxone—ESR1—Leptin signaling pathway—IL1RN—ankylosing spondylitis	7.7e-05	0.0132	CbGpPWpGaD
Naloxone—TLR4—Immune System—ERAP1—ankylosing spondylitis	7.68e-05	0.0132	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	7.66e-05	0.00433	CcSEcCtD
Naloxone—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	7.66e-05	0.00433	CcSEcCtD
Naloxone—Pain—Dexamethasone—ankylosing spondylitis	7.59e-05	0.00429	CcSEcCtD
Naloxone—Pain—Betamethasone—ankylosing spondylitis	7.59e-05	0.00429	CcSEcCtD
Naloxone—Nervous system disorder—Prednisone—ankylosing spondylitis	7.58e-05	0.00428	CcSEcCtD
Naloxone—TLR4—Innate Immune System—HLA-C—ankylosing spondylitis	7.58e-05	0.013	CbGpPWpGaD
Naloxone—Tachycardia—Prednisone—ankylosing spondylitis	7.54e-05	0.00426	CcSEcCtD
Naloxone—Skin disorder—Prednisone—ankylosing spondylitis	7.51e-05	0.00424	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisone—ankylosing spondylitis	7.47e-05	0.00422	CcSEcCtD
Naloxone—CREB1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	7.31e-05	0.0125	CbGpPWpGaD
Naloxone—OPRM1—IL4-mediated signaling events—CD40LG—ankylosing spondylitis	7.24e-05	0.0124	CbGpPWpGaD
Naloxone—OPRM1—IL4-mediated signaling events—IL10—ankylosing spondylitis	7.24e-05	0.0124	CbGpPWpGaD
Naloxone—TLR4—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	7.17e-05	0.0123	CbGpPWpGaD
Naloxone—TLR4—Immune System—CARD9—ankylosing spondylitis	7.03e-05	0.012	CbGpPWpGaD
Naloxone—Asthenia—Triamcinolone—ankylosing spondylitis	7.02e-05	0.00396	CcSEcCtD
Naloxone—Abdominal pain—Betamethasone—ankylosing spondylitis	7.01e-05	0.00396	CcSEcCtD
Naloxone—Abdominal pain—Dexamethasone—ankylosing spondylitis	7.01e-05	0.00396	CcSEcCtD
Naloxone—Body temperature increased—Betamethasone—ankylosing spondylitis	7.01e-05	0.00396	CcSEcCtD
Naloxone—Body temperature increased—Dexamethasone—ankylosing spondylitis	7.01e-05	0.00396	CcSEcCtD
Naloxone—Asthenia—Methylprednisolone—ankylosing spondylitis	7e-05	0.00396	CcSEcCtD
Naloxone—Paraesthesia—Prednisone—ankylosing spondylitis	6.94e-05	0.00392	CcSEcCtD
Naloxone—Convulsion—Methotrexate—ankylosing spondylitis	6.86e-05	0.00387	CcSEcCtD
Naloxone—CREB1—DAP12 interactions—HLA-C—ankylosing spondylitis	6.81e-05	0.0117	CbGpPWpGaD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	6.69e-05	0.00378	CcSEcCtD
Naloxone—Diarrhoea—Methylprednisolone—ankylosing spondylitis	6.68e-05	0.00377	CcSEcCtD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	6.54e-05	0.0112	CbGpPWpGaD
Naloxone—TLR4—Spinal Cord Injury—TNF—ankylosing spondylitis	6.38e-05	0.0109	CbGpPWpGaD
Naloxone—Asthenia—Betamethasone—ankylosing spondylitis	6.37e-05	0.0036	CcSEcCtD
Naloxone—Asthenia—Dexamethasone—ankylosing spondylitis	6.37e-05	0.0036	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—ankylosing spondylitis	6.33e-05	0.00358	CcSEcCtD
Naloxone—Nausea—Prednisolone—ankylosing spondylitis	6.32e-05	0.00357	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—ankylosing spondylitis	6.27e-05	0.00354	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—ankylosing spondylitis	6.24e-05	0.00353	CcSEcCtD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	6.24e-05	0.0107	CbGpPWpGaD
Naloxone—Vomiting—Triamcinolone—ankylosing spondylitis	6.22e-05	0.00351	CcSEcCtD
Naloxone—Vomiting—Methylprednisolone—ankylosing spondylitis	6.2e-05	0.0035	CcSEcCtD
Naloxone—Body temperature increased—Prednisone—ankylosing spondylitis	6.11e-05	0.00345	CcSEcCtD
Naloxone—Abdominal pain—Prednisone—ankylosing spondylitis	6.11e-05	0.00345	CcSEcCtD
Naloxone—Diarrhoea—Dexamethasone—ankylosing spondylitis	6.07e-05	0.00343	CcSEcCtD
Naloxone—Diarrhoea—Betamethasone—ankylosing spondylitis	6.07e-05	0.00343	CcSEcCtD
Naloxone—ESR1—AP-1 transcription factor network—IL10—ankylosing spondylitis	5.82e-05	0.00997	CbGpPWpGaD
Naloxone—Nausea—Triamcinolone—ankylosing spondylitis	5.81e-05	0.00328	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—ankylosing spondylitis	5.8e-05	0.00328	CcSEcCtD
Naloxone—Nausea—Methylprednisolone—ankylosing spondylitis	5.8e-05	0.00327	CcSEcCtD
Naloxone—CREB1—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	5.76e-05	0.00986	CbGpPWpGaD
Naloxone—Dyspnoea—Methotrexate—ankylosing spondylitis	5.76e-05	0.00325	CcSEcCtD
Naloxone—CREB1—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	5.66e-05	0.00969	CbGpPWpGaD
Naloxone—Vomiting—Dexamethasone—ankylosing spondylitis	5.64e-05	0.00319	CcSEcCtD
Naloxone—Vomiting—Betamethasone—ankylosing spondylitis	5.64e-05	0.00319	CcSEcCtD
Naloxone—TLR4—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	5.6e-05	0.00959	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	5.58e-05	0.00315	CcSEcCtD
Naloxone—Asthenia—Prednisone—ankylosing spondylitis	5.54e-05	0.00313	CcSEcCtD
Naloxone—Pain—Methotrexate—ankylosing spondylitis	5.52e-05	0.00312	CcSEcCtD
Naloxone—CREB1—MyD88-independent cascade—TLR4—ankylosing spondylitis	5.43e-05	0.0093	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	5.4e-05	0.00925	CbGpPWpGaD
Naloxone—Diarrhoea—Prednisone—ankylosing spondylitis	5.29e-05	0.00299	CcSEcCtD
Naloxone—Nausea—Betamethasone—ankylosing spondylitis	5.27e-05	0.00298	CcSEcCtD
Naloxone—Nausea—Dexamethasone—ankylosing spondylitis	5.27e-05	0.00298	CcSEcCtD
Naloxone—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—ankylosing spondylitis	5.18e-05	0.00887	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	5.13e-05	0.00879	CbGpPWpGaD
Naloxone—Abdominal pain—Methotrexate—ankylosing spondylitis	5.1e-05	0.00288	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—ankylosing spondylitis	5.1e-05	0.00288	CcSEcCtD
Naloxone—Vomiting—Prednisone—ankylosing spondylitis	4.91e-05	0.00278	CcSEcCtD
Naloxone—CREB1—Activated TLR4 signalling—TLR4—ankylosing spondylitis	4.88e-05	0.00836	CbGpPWpGaD
Naloxone—CREB1—B Cell Activation—CD79A—ankylosing spondylitis	4.8e-05	0.00823	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	4.71e-05	0.00806	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	4.68e-05	0.00802	CbGpPWpGaD
Naloxone—CREB1—Immune System—KIR3DL1—ankylosing spondylitis	4.67e-05	0.008	CbGpPWpGaD
Naloxone—OPRD1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	4.66e-05	0.00798	CbGpPWpGaD
Naloxone—Asthenia—Methotrexate—ankylosing spondylitis	4.63e-05	0.00262	CcSEcCtD
Naloxone—CREB1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	4.59e-05	0.00787	CbGpPWpGaD
Naloxone—Nausea—Prednisone—ankylosing spondylitis	4.59e-05	0.00259	CcSEcCtD
Naloxone—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	4.5e-05	0.0077	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—HLA-B—ankylosing spondylitis	4.48e-05	0.00767	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—ERAP1—ankylosing spondylitis	4.42e-05	0.00757	CbGpPWpGaD
Naloxone—Diarrhoea—Methotrexate—ankylosing spondylitis	4.42e-05	0.0025	CcSEcCtD
Naloxone—TLR4—Immune System—HLA-C—ankylosing spondylitis	4.41e-05	0.00756	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CARD9—ankylosing spondylitis	4.21e-05	0.00721	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	4.11e-05	0.00704	CbGpPWpGaD
Naloxone—Vomiting—Methotrexate—ankylosing spondylitis	4.11e-05	0.00232	CcSEcCtD
Naloxone—CREB1—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	4.09e-05	0.00701	CbGpPWpGaD
Naloxone—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	4.09e-05	0.007	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—HLA-B—ankylosing spondylitis	4.03e-05	0.00689	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	3.99e-05	0.00684	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—CRP—ankylosing spondylitis	3.96e-05	0.00678	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	3.85e-05	0.0066	CbGpPWpGaD
Naloxone—Nausea—Methotrexate—ankylosing spondylitis	3.84e-05	0.00217	CcSEcCtD
Naloxone—TLR4—Immune System—IL1RN—ankylosing spondylitis	3.83e-05	0.00656	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	3.82e-05	0.00655	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	3.81e-05	0.00652	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	3.5e-05	0.006	CbGpPWpGaD
Naloxone—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	3.45e-05	0.00592	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD79A—ankylosing spondylitis	3.37e-05	0.00576	CbGpPWpGaD
Naloxone—CREB1—Disease—ANTXR2—ankylosing spondylitis	3.27e-05	0.0056	CbGpPWpGaD
Naloxone—ESR1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	3.1e-05	0.00531	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—CRP—ankylosing spondylitis	3.1e-05	0.00531	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	3.05e-05	0.00522	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—PTGER4—ankylosing spondylitis	3.04e-05	0.00521	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	2.96e-05	0.00507	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1R2—ankylosing spondylitis	2.83e-05	0.00484	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	2.81e-05	0.00482	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	2.8e-05	0.00479	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	2.8e-05	0.00479	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL1A—ankylosing spondylitis	2.76e-05	0.00473	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD40LG—ankylosing spondylitis	2.74e-05	0.0047	CbGpPWpGaD
Naloxone—CREB1—Immune System—ERAP1—ankylosing spondylitis	2.68e-05	0.00459	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.67e-05	0.00458	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—PTGER4—ankylosing spondylitis	2.67e-05	0.00457	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	2.66e-05	0.00455	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HLA-C—ankylosing spondylitis	2.64e-05	0.00453	CbGpPWpGaD
Naloxone—TLR4—Immune System—HLA-B—ankylosing spondylitis	2.61e-05	0.00447	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-C—ankylosing spondylitis	2.54e-05	0.00435	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	2.46e-05	0.00422	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	2.46e-05	0.00422	CbGpPWpGaD
Naloxone—CREB1—Immune System—CARD9—ankylosing spondylitis	2.45e-05	0.0042	CbGpPWpGaD
Naloxone—TLR4—Immune System—HLA-A—ankylosing spondylitis	2.42e-05	0.00414	CbGpPWpGaD
Naloxone—TLR4—Immune System—CRP—ankylosing spondylitis	2.31e-05	0.00395	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—PTGER4—ankylosing spondylitis	2.25e-05	0.00386	CbGpPWpGaD
Naloxone—CREB1—Adipogenesis—TNF—ankylosing spondylitis	2.06e-05	0.00353	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD79A—ankylosing spondylitis	1.94e-05	0.00332	CbGpPWpGaD
Naloxone—CREB1—Disease—B3GNT2—ankylosing spondylitis	1.93e-05	0.0033	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	1.78e-05	0.00305	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	1.72e-05	0.00295	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	1.72e-05	0.00294	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD40LG—ankylosing spondylitis	1.58e-05	0.0027	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PTGER4—ankylosing spondylitis	1.57e-05	0.00268	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HLA-B—ankylosing spondylitis	1.56e-05	0.00268	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PTGER4—ankylosing spondylitis	1.56e-05	0.00267	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-C—ankylosing spondylitis	1.54e-05	0.00264	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	1.52e-05	0.0026	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	1.51e-05	0.00258	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-B—ankylosing spondylitis	1.5e-05	0.00257	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TNF—ankylosing spondylitis	1.4e-05	0.0024	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-A—ankylosing spondylitis	1.39e-05	0.00238	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CRP—ankylosing spondylitis	1.38e-05	0.00237	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	1.37e-05	0.00234	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1RN—ankylosing spondylitis	1.34e-05	0.00229	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—TLR4—ankylosing spondylitis	1.33e-05	0.00227	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—B3GNT2—ankylosing spondylitis	1.31e-05	0.00224	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	1.27e-05	0.00218	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD79A—ankylosing spondylitis	1.17e-05	0.00201	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	1.16e-05	0.00198	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—MMP3—ankylosing spondylitis	1.11e-05	0.00191	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	1.11e-05	0.00191	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—MMP3—ankylosing spondylitis	1.11e-05	0.0019	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	1.06e-05	0.00182	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	9.93e-06	0.0017	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MMP3—ankylosing spondylitis	9.74e-06	0.00167	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1A—ankylosing spondylitis	9.63e-06	0.00165	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD40LG—ankylosing spondylitis	9.58e-06	0.00164	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTGER4—ankylosing spondylitis	9.25e-06	0.00158	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTGER4—ankylosing spondylitis	9.22e-06	0.00158	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-B—ankylosing spondylitis	9.11e-06	0.00156	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-A—ankylosing spondylitis	8.44e-06	0.00145	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MMP3—ankylosing spondylitis	8.24e-06	0.00141	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.08e-06	0.00138	CbGpPWpGaD
Naloxone—CREB1—Immune System—CRP—ankylosing spondylitis	8.05e-06	0.00138	CbGpPWpGaD
Naloxone—CREB1—Disease—HLA-A—ankylosing spondylitis	7.79e-06	0.00133	CbGpPWpGaD
Naloxone—CREB1—Immune System—TLR4—ankylosing spondylitis	7.72e-06	0.00132	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—ankylosing spondylitis	7.09e-06	0.00121	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.83e-06	0.00117	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP3—ankylosing spondylitis	6.59e-06	0.00113	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP3—ankylosing spondylitis	6.56e-06	0.00112	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	6.42e-06	0.0011	CbGpPWpGaD
Naloxone—ALB—Metabolism—B3GNT2—ankylosing spondylitis	6.38e-06	0.00109	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.06e-06	0.00104	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP3—ankylosing spondylitis	5.76e-06	0.000986	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	5.59e-06	0.000957	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	5.25e-06	0.000899	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP3—ankylosing spondylitis	4.87e-06	0.000833	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP3—ankylosing spondylitis	4.31e-06	0.000739	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	3.44e-06	0.00059	CbGpPWpGaD
